ijerph-logo

Journal Browser

Journal Browser

Direct and Indirect Complications of COVID-19 Pandemic on Cardiovascular Health and Diseases

Special Issue Editor


E-Mail Website
Guest Editor
Diabetes Research Program, New York University Grossman Medical Center, New York, NY 10012, USA
Interests: cardiovascular diseases; vascular aging; sirtuins; mitochondrial function; heart failure; ischemia reperfusion injury; cell senescence; endothelial biology; induced pluripotent stem cell biology

Special Issue Information

Dear Colleagues,

The COVID-19 pandemic has had a huge global impact, claiming millions of lives. In addition to being a health burden, it has also imposed deleterious social and economic consequences for millions worldwide. Mortality caused by COVID-19 has raised several questions to the scientific community regarding the exact cause of death. The microbiology and history of Coronaviridae family are known to cause mild respiratory tract disorders—severe in the case of SARS—but not at the level of a pandemic. Within COVID-19 mortalities, the percentage of deaths caused by underlying cardiovascular diseases has been significantly high. My own enquiries, informed by my strong Medical Microbiology background and expertise in cardiovascular disease and physiology, have raised several questions of this nature, and I would like to share my thoughts and scientific reality with our community and the global population. 

This Special Issue welcomes articles and discussions focused on CVDs and COVID-19.  Important questions to address are as follows: Is there direct evidence linking COVID-19 to heart and vascular diseases? Is COVID-19 associated with CVDs wherein the patients are terminally ill or already suffering from an END-STAGE CVD? Does COVID-19 pose immediate and long-term complications for accelerated CVDs? Finally, are cardiovascular deaths independent of COVID-19, even though patients are tested positive at end stages or near death? I encourage honest and unbiased opinions from our scientific community within this Special Issue to address the important topic of COVID-19 and CVDs.

Dr. Gautham Yepuri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • CVDs
  • heart failure
  • hypoxia
  • ischemic injury
  • mitochondrial dysfunction
  • senescence
  • vascular dysfunction
  • atherosclerosis
  • hypertension
  • panic induced heart failure
  • myocardial infarction

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 728 KiB  
Article
Impact of the COVID-19 Pandemic on Pulmonary Hypertension Patients: Insights from the BNP-PL National Database
by Aleksandra Mamzer, Marcin Waligora, Grzegorz Kopec, Katarzyna Ptaszynska-Kopczynska, Marcin Kurzyna, Szymon Darocha, Michal Florczyk, Ewa Mroczek, Tatiana Mularek-Kubzdela, Anna Smukowska-Gorynia, Michal Wrotynski, Lukasz Chrzanowski, Olga Dzikowska-Diduch, Katarzyna Perzanowska-Brzeszkiewicz, Piotr Pruszczyk, Ilona Skoczylas, Ewa Lewicka, Piotr Blaszczak, Danuta Karasek, Beata Kusmierczyk-Droszcz, Katarzyna Mizia-Stec, Karol Kaminski, Wojciech Jachec, Malgorzata Peregud-Pogorzelska, Anna Doboszynska, Zbigniew Gasior, Michal Tomaszewski, Agnieszka Pawlak, Wieslawa Zablocka, Robert Ryczek, Katarzyna Widejko-Pietkiewicz and Jaroslaw D. Kasprzakadd Show full author list remove Hide full author list
Int. J. Environ. Res. Public Health 2022, 19(14), 8423; https://doi.org/10.3390/ijerph19148423 - 10 Jul 2022
Cited by 9 | Viewed by 3289
Abstract
We aimed to evaluate the clinical course and impact of the SARS-CoV-2 pandemic on the rate of diagnosis and therapy in the complete Polish population of patients (pts) with pulmonary arterial hypertension (PAH-1134) and CTEPH (570 pts) treated within the National Health Fund [...] Read more.
We aimed to evaluate the clinical course and impact of the SARS-CoV-2 pandemic on the rate of diagnosis and therapy in the complete Polish population of patients (pts) with pulmonary arterial hypertension (PAH-1134) and CTEPH (570 pts) treated within the National Health Fund program and reported in the national BNP-PL database. Updated records of 1704 BNP-PL pts collected between March and December 2020 were analyzed with regard to incidence, clinical course and mortality associated with COVID-19. Clinical characteristics of the infected pts and COVID-19 decedents were analyzed. The rates of new diagnoses and treatment intensification in this period were studied and collated to the proper intervals of the previous year. The incidence of COVID-19 was 3.8% (n = 65) (PAH, 4.1%; CTEPH, 3.2%). COVID-19-related mortality was 28% (18/65 pts). Those who died were substantially older and had a more advanced functional WHO class and more cardiovascular comorbidities (comorbidity score, 4.0 ± 2.1 vs. 2.7 ± 1.8; p = 0.01). During the pandemic, annualized new diagnoses of PH diminished by 25–30% as compared to 2019. A relevant increase in total mortality was also observed among the PH pts (9.7% vs. 5.9% pre-pandemic, p = 0.006), whereas escalation of specific PAH/CTEPH therapies occurred less frequently (14.7% vs. 21.6% pre-pandemic). The COVID-19 pandemic has affected the diagnosis and treatment of PH by decreasing the number of new diagnoses, escalating therapy and enhancing overall mortality. Pulmonary hypertension is a risk factor for worsened course of COVID-19 and elevated mortality. Full article
Show Figures

Figure 1

Back to TopTop